Literature DB >> 6385823

Creutzfeldt-Jakob disease of long duration: clinicopathological characteristics, transmissibility, and differential diagnosis.

P Brown, P Rodgers-Johnson, F Cathala, C J Gibbs, D C Gajdusek.   

Abstract

Five to 10% of patients with Creutzfeldt-Jakob disease have a clinical course that extends for 2 years or more. In the present series 33 (9%) of 357 histopathologically verified cases, including 15 (7%) of 225 transmitted cases, fell into this long-duration category, the longest transmitted case having had a 13-year duration. As a group these cases were characterized by a higher familial representation (30%), a younger age at onset (average, 48 years), and lower frequencies of myoclonus (79%) and periodic electroencephalographic activity (45%) than occur in series of unselected cases. The clinical course most often showed a long, very slowly progressive first stage, with symptoms limited to intellectual deterioration or behavioral abnormalities, followed by a shorter, rapidly progressive terminal stage with both mental and physical deterioration. Although transmission of disease by primate inoculation was less successful in this group of long-duration cases (64%) than in cases of shorter duration (88%), incubation periods and durations of illness in the inoculated animals bore no relation to the duration of illness in the patients. Clinical differentiation from other chronic dementing processes, particularly Alzheimer's disease, can prove impossible; however, the correct pathological diagnosis was readily evident by light microscopic examination, and spongiosis was at least as prominent as gliosis in all but 4 (15%) of the 27 patients studied postmortem, the same frequency found in case series not selected for length of illness.

Entities:  

Mesh:

Year:  1984        PMID: 6385823     DOI: 10.1002/ana.410160305

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  23 in total

1.  Progressive aphasia with rapidly progressive dementia in a 49 year old woman.

Authors:  J D Greene; J R Hodges; J W Ironside; C P Warlow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-02       Impact factor: 10.154

2.  Research on familial Creutzfeldt-Jakob disease (FCJD) resulting in presymptomatic testing: implications for the Human Genome Project.

Authors:  Janet E Ulm; Cindy L Vnencak-Jones; Patrick Bosque
Journal:  J Genet Couns       Date:  1993-03       Impact factor: 2.537

3.  Considerations on a group of 13 patients with Creutzfeldt-Jakob disease in the region of Parma (Italy)

Authors:  G Trabattoni; A Lechi; L Bettoni; G Macchi; P Brown
Journal:  Eur J Epidemiol       Date:  1990-09       Impact factor: 8.082

4.  Incidence of Creutzfeldt-Jakob disease in Taiwan: a prospective 10-year surveillance.

Authors:  Chien-Jung Lu; Yu Sun; Shun-Sheng Chen
Journal:  Eur J Epidemiol       Date:  2010-03-24       Impact factor: 8.082

Review 5.  The prion strain phenomenon: molecular basis and unprecedented features.

Authors:  Rodrigo Morales; Karim Abid; Claudio Soto
Journal:  Biochim Biophys Acta       Date:  2006-12-15

Review 6.  Clinical, laboratory, and morphological diagnosis of human subacute spongiform encephalopathies in Byelorussia.

Authors:  I I Protas; N D Kolomietz; M K Nedzvedz; E K Milkamanovich
Journal:  Eur J Epidemiol       Date:  1991-09       Impact factor: 8.082

Review 7.  Epidemiological surveillance of Creutzfeldt-Jakob disease in the United Kingdom.

Authors:  R G Will
Journal:  Eur J Epidemiol       Date:  1991-09       Impact factor: 8.082

8.  Diagnosing Creutzfeldt-Jakob disease.

Authors:  R Will; M Zeidler
Journal:  BMJ       Date:  1996-10-05

9.  Unusual EEG findings in a case of Creutzfeldt-Jakob disease.

Authors:  J P Malin; K Weissenborn; J Haas; G F Walter
Journal:  J Neurol       Date:  1987-01       Impact factor: 4.849

10.  Identification of a second bovine amyloidotic spongiform encephalopathy: molecular similarities with sporadic Creutzfeldt-Jakob disease.

Authors:  Cristina Casalone; Gianluigi Zanusso; Pierluigi Acutis; Sergio Ferrari; Lorenzo Capucci; Fabrizio Tagliavini; Salvatore Monaco; Maria Caramelli
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.